News
Publications
Multimedia
Conferences
Webcasts
Resources
Subscribe

Spotlight -

Drug Development|

Quality Systems

News|Articles|December 4, 2013

The Impact of Biosimilars on the Innovator Market

Author(s)Pharmaceutical Technology Editors

Jill E. Sackman, D.V.M., PhD, senior consultant at Numerof & Associates, Inc. discusses the market forces impacting biopharmaceutical manufacturing

Jill E. Sackman, D.V.M., PhD, senior consultant atNumerof & Associates, Inc. discusses the market forces impacting biopharmaceutical manufacturing.

For more videos tune in to:

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related Content

Roche Gets Priority Review for Enspryng; Announces Sequencing Platform

BySusan Haigney

June 30th 2026

Regulatory Developments Impacting Biologics

BySusan J. Schniepp,Siegfried Schmitt,Susan Haigney

June 30th 2026

Oxylanthanum carbonate was rejected for the 2nd time by the FDA

Manufacturing Deficiencies Behind FDA's Oxylanthanum Carbonate Rejection

ByZachary Zubulake

June 30th 2026

Antibody drug conjugate in blue with four drug compounds linked to IgG immunoglobulin; ADC in blue against blue background 3d render | Image Credit: ©huenstructurebio.com -stock.adobe.com

Lonza Increases HPAPI Production at Visp Facility

BySusan Haigney

June 30th 2026

Pill with American flag wrapped around it and red ball inside | Image Credit: ©fabioberti.it -stock.adobe.com

FDA Chooses 7 Companies for PreCheck Pilot

BySusan Haigney

June 30th 2026

Trending on Pharmaceutical Technology

Roche Gets Priority Review for Enspryng; Announces Sequencing Platform

FDA Chooses 7 Companies for PreCheck Pilot

Manufacturing Deficiencies Behind FDA's Oxylanthanum Carbonate Rejection

Lonza Increases HPAPI Production at Visp Facility

Regulatory Developments Impacting Biologics